APOL1 Renal-Risk Variants Do Not Associate With Incident Cardiovascular Disease or Mortality in the Systolic Blood Pressure Intervention Trial

APOL1 Renal-Risk Variants Do Not Associate With Incident Cardiovascular Disease or Mortality in the Systolic Blood Pressure Intervention Trial

Relationships between apolipoprotein L1 gene (APOL1) renal-risk variants (RRVs) and cardiovascular disease (CVD) remain controversial. To clarify associations between APOL1 and CVD, a total of 2568 African American Systolic Blood Pressure Intervention Trial (SPRINT) participants were assessed for th...

Full description

Bibliographic Details
Main Authors: Barry I. Freedman, Michael V. Rocco, Jeffrey T. Bates, Michel Chonchol, Amret T. Hawfield, James P. Lash, Vasilios Papademetriou, John R. Sedor, Karen Servilla, Paul L. Kimmel, Barry M. Wall, Nicholas M. Pajewski
Format: Article
Language:English
Published: Elsevier 2017-07-01
Series:Kidney International Reports
Subjects:
African Americans
albuminuria
APOL1
cardiovascular disease
chronic kidney disease
SPRINT
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024917300621

Internet

http://www.sciencedirect.com/science/article/pii/S2468024917300621

Similar Items